Breaking News, Collaborations & Alliances

VERAXA and Quadira Enter ADC Development Partnership

To develop a suite of novel ADCs for the treatment of oncological conditions.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), an ADC engineering and functional antibody screening company, has entered into a partnership with Quadira Biosciences AG of Zug, Switzerland, to develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage VERAXA’s advanced and proprietary position-true click-chemistry-based drug conjugation technology with Quadira’s 3D cellular assay and assessment systems. The agreement says VERAXA will b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters